



PHYTOCHEMICAL AND ANTIDIABETIC  
INVESTIGATIONS OF “*TETRACERA SCANDENS*”  
LINN.

BY

ABDULRASHID UMAR

A thesis submitted in fulfilment of the requirement for  
the degree of Masters of Science in Pharmaceutical  
Chemistry

Kulliyyah of Pharmacy

International Islamic University  
Malaysia

APRIL 2011

## ABSTRACT

Different parts (leaves, stems and roots) of *T. scandens* L. are used in folk remedies by various indigenous peoples in different countries for the treatment of rheumatism, lowering hypertension, lowering blood pressure, inflammatory diseases, hepatitis, internal pains, urinary disorders, dysentery, child birth, sore throat, gout and diabetes related infirmities. The present work investigates the anti-diabetic activity of the polar and non-polar extracts of *T. scandens* L. leaves *in vivo* in alloxan induced diabetic and normal rats. This study was conducted *in vivo* and comparison was made with standard antidiabetic drug, glibenclamide (GLBC). Glucose levels in male albino rats (Wister strain) with hyperglycemia induced by alloxan (160 mg/kg b.w.) were determined after the oral administration of the aqueous (AQ) methanolic (MEOH), butanol (BuOH), ethylacetate (EtOAc) and dichloromethane (DCM) extracts. Four doses of AQ and MEOH extract (250, 500, 1000 and 2000 mg/kg b.w.) and a fixed dose of 500mg/kg b.w of BuOH, EtOAc and DCM extracts were evaluated. All extracts exhibited significant anti-hyperglycemic activity in alloxan induced diabetic rats, except DCM, however in normal rats no hypoglycemic activity was observed among all the extracts, when compared with both +ve & -ve controlled. The antidiabetic activity was found to be comparable to that of the effect produced by GLBC (0.25 mg/kg b.w.). The LD<sub>50</sub> of both AQ and MEOH extracts was found to be more than 5000 mg/kg body weight and no lethal toxicity was observed within this range. This study provides scientific evidence about the leaves of *T. scandens* L. which possess antidiabetic agents and justifies its utility by the local herbalists to treat diabetes in Malaysia. Phytochemical investigation and chromatographic fractionation of MEOH extract of the leaves of *T. scandens* L. led to the isolation and structure elucidation of two new and three known flavonoids, and two known terpenoids. The occurrence of kaempferol, quercetin, isoscutellarein, 5,7,8,3',5,-pentahydroxyflavone, 2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')-kaempferol-3''-O-β-D-glucopyranoside, stigmasterol and betullinic acid in the leaves of *T. scandens* L. is being reported for the first time.

**Keywords:** *Tetracera scandens* Linn., Dilleniaceae, Antidiabetic activity, Phytoconstituents


## خلاصة البحث

يُستخدم العديد من أجزاء الـ *T. scandens* L. (الأوراق، السوق والجذور) في الأدوية العشبية المستخدمة من قبل السكان الأصليين في العديد من البلدان لمعالجة الرثية، خفض ارتفاع الضغط، خفض ضغط الدم، الأمراض الالتهابية، التهاب الكبد، الآلام الداخلية، الاضطرابات البولية، الزحار، عند الولادة، التهاب الحلق، النقرس والعيوب المرتبطة بالداء السكري. يتحرى العمل الحالي الفعالية المضادة لارتفاع السكر للخلاصات القسطية لأوراق *T. scandens* في الجسم الحي في الجرذان المصابة بداء السكري المحرض بالألوكسان وفي الجرذان السليمة. تمت هذه الدراسة في الجسم الحي وأجريت المقارنة مع دواء مرجعي مضاد للسكري هو (glibenclamide (GLBC). تم قياس مستويات الغوكوز عند ذكور الجرذان البيضاء (Wister strain) المصابة بارتفاع السكر المحرض بالألوكسان (160 mg/kg b.w.) بعد الإغطاء الفموي للخلاصات المائية (AQ)، الميتانولية (MEOH)، البوتانولية (BuOH)، نحالة الإيتيل أسيتات (EtOAc) والديكلوروميثان (DCM). تم تقييم أربع جرعات من الخلاصات المائية والميتانولية (250, 500mg/kg b.w. وجرعة ثابتة من الخلاصة البوتانولية (500, 1000 and 2000 mg/kg b.w.)). كل الخلاصات أظهرت فعالية مهمة مضادة لارتفاع السكر في الجرذان المصابة بداء السكري المحرض بالألوكسان، باستثناء خلاصة الديكلوروميثان، لكن لم يلاحظ أي فعالية خافضة للسكر في الجرذان السليمة في كل الخلاصات، وذلك مقارنة بالشاهد +ve & -ve. تبين أيضاً أن الفعالية المضادة للسكري يمكن مقارنتها بتلك المحدثه بالـ GLBC (0.25 mg/kg b.w.). الـ LD<sub>50</sub> للخلاصتين المائية والميتانولية وُجدت أكثر من 5000 mg/kg من وزن الجسم ولم يلاحظ أية سُمية قاتلة ضمن هذا المجال. إن هذه الدراسة توفر بوضوح دليلاً حول أوراق؟؟؟ التي تملك عوامل مضادة للسكري وتفسر استخدامها من قبل المعالجين بالأعشاب المحليين لمعالجة الداء السكري في ماليزيا. التحريات الفيتوكيميائية والتجزئة للخلاصة الميتانولية لأوراق؟؟؟ قادت إلى عزل وتحديد البنية لثلاثة فلافونويدات جديدة واثنين معروفين، وكذلك مركبين معروفين من التربينويدات. هذه هي المرة الأولى التي يُنشر فيها وجود الـ Kaempferol، Quercetin، isoscutellarein، -3', 5'-pentahydroxyflavone، 2, 5, 7, 8, 3', 5'-pentahydroxy stilbene-(4→O→4''')-kaempferol-3''-O-β-D-glucopyranoside (Stigmasterol) و (Betullinic acid) في أوراق *T. scandens* L.

الكلمات المفتاحية: *Tetracera scandens* Linn., Dilleniaceae، الفعالية المضادة للسكري، المكونات النباتية


## APPROVAL PAGE

I certify that I have supervised and read this study and that in my opinion; it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master of Pharmaceutical Chemistry.



Qamar U. Ahmed  
Supervisor

I certify that I have read this study and that in my opinion; it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master of Pharmaceutical Chemistry.




Ahmed Merzouk  
Examiner

This thesis was submitted to the Department of Pharmaceutical Chemistry and is accepted as a fulfilment of the requirement for the degree of Master of Pharmaceutical Chemistry.



Ahmed Merzouk  
Head of Department  
Pharmaceutical Chemistry

This thesis was submitted to the Kulliyyah of Pharmacy and is accepted as a fulfilment of the requirement for the degree of Master of Pharmaceutical Chemistry.




Tariq Abdul Razak  
Dean, Kulliyyah of Pharmacy

## DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Abdulrashid Umar

Signature.....

Date.....

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA


**DECLARATION OF COPYRIGHT AND AFFIRMATION  
OF FAIR USE OF UNPUBLISHED RESEARCH**

Copyright © 2011 by International Islamic University Malaysia. All rights reserved.


**PHYTOCHEMICAL AND ANTIDIABETIC INVESTIGATIONS OF  
“TETRACERA SCANDENS” LINN.**

I hereby affirm that The International Islamic University Malaysia (IIUM) hold all rights in the copyright of this work and henceforth any reproduction or use in any form or by means whatsoever is prohibited without the written consent of IIUM. No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted. in any form or by means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder.

Affirmed by Abdulrashid Umar



Signature



Date

*To my beloved and respected family of Usmaniyya, thank you all for your kind support love and care. Special thank to you dear great mum, your selfless spiritual imparted moral support have always been with me helping me in achieving my goals. Tons of thanks to my beloved dad, you've sacrificed both personally and professionally for me to chase down my dreams. I have to express my feelings of appreciations to you my dear respected grandma, even though my tongue is unable to pronounce enough words to praise for your wonderful spiritual advices, most especially if I remember your love towards me, advice, Islamic motivations, and all such beautiful words that always come out of your mouth that stir the love of Allah Almighty and His Most beloved Messenger Muhammad (SAW) in the depth of my heart. I hope you know how much it has meant to me and how important you are to me, blessings of Allah (SWA) be always with your souls of the lovers of Prophet Muhammad SAW.*

## ACKNOWLEDGEMENTS

Beginning is always starting by praising Allah (SWA) Almighty, and may His peace and blessings be upon our beloved prophet Muhammad (SAW).

Time has come to express my sincere gratitude to my principal supervisor Assoc. Prof. Dr Qamar Uddin Ahmed for his invaluable advice, and guidance throughout the course of my study and research for the degree of Master of Science. He takes care of me from my study life to personal development gives me lots of opportunity to explore and to learn and provides me the freedom and flexibility to be creative with my work and at the same time pushing me to expand my productivity and knowledge beyond what I thought possible. Always provides me with insight in chemical knowledge and encourages me to apply appropriate methodology in my research, am opportune to have had you as my supervisor, in fact you are chapter in my life that I will look back on with fond memories and I look forward to the many chapters that lie head both as your friend and student. May Allah (SWA) bless you and your family abundantly.

Deep appreciation is extended to my co supervisor Assoc. Prof Dr. Bala Muhammad Yauri for his immense patience, guidance and support. He provided me great opportunity to learn various aspects of pharmacological researches.

Real motivations and inspirations especially if it comes to academic field is the responsibility of Dr. Abubakar Abdullahi Kebbe, it has been a pleasure and an honour to be with you. In fact your constant words of encouragement provided me confidence to excel.

You deserved to be acknowledged dear research colleagues, Bashar Bello SD, Abubakar Suleiman, it is a great pleasure to always remember how silica gel contributed to a tremendous transformation of our research skills hmm!!!, you have always been willing to lend a helping hand , having such wonderful team is a proud. Am grateful to Sir. Noor Zihan Binti Abdul Karim, Science officer, Pharmaceutical Chemistry Department for all your help in chemical supply and managing our medicinal and organic research laboratory persuasively. The same thanks go to the laboratory technicians: Br. Mohd Razif for his help in FTIR, Br. Mohd Najib for UV and GC-MS, Sir. Fatimah for HPLC and Sir. Azura for her always assistance in monitoring laboratory equipments. I am grateful to Br. Zahid for his help with NMR under supervision of Assoc. Prof. Dr. Jalifa and Br. Alefee for EI-MS both from National University of Malaysia (UKM).

Tons of thanks for your scholarly advice Assoc. Prof. Dr Ibrahim Shogar (Advisor for International students. IIUM Kuantan) there were many days when I thought I would never see the light at the end of the tunnel but you were always there to brighten my day and help push me along, May Allah reward you abundantly.

I have to express my word of thanks to the entire staff of Pharmaceutical Chemistry Department for their help support and scholarly advice. Most especially to our former head of the department Dr. Mohammed B. Awang who has always been



with us to give us constructive advices, so also the present Head, Department of Pharmaceutical Chemistry, Dr Ahmed Merzouk, who has always been there to oblige our request and optimize our laboratory standard. Thank you Prof. Dr. Abbas, Postgraduate student advisor, Kulliyyah of Pharmacy for your all academic advices provided. I've to acknowledge a potential Br. Erman Shah, Science Officer, Department of Basic Medical Sciences, whose help is extended to the entire faculty; he is always waiting for people to lay hand of assistance, fortunate are you.

You are worthy to be acknowledged Abubakar Malami (a distinguished and wonderful causin), Saif el Islam, Sheikh Aslam, Ashraf (Osama), Zulkifli, Hasan sheikh, Omer el Hadi, Hafizarul, Abdullahi Ahmad, Aminu Ishaka (Dr), Hassan Muhammad Y (Dr), Ami Br. Abdul Mun'im, Akbar J., Abdulrazak, Mansur, Hafiz Huzazi, Habibi, Haitham Osama, Essam and Magdi. You are such powerful example of young scientists and fantastic human beings.

Same acknowledgement goes to you all dear friends, whose name were not mentioned, this is just due to a space alert however feelings of appreciations have always been with you.

Tons of thanks to research management center (RMC) International Islamic University Malaysia allocating fund to this research which eventually led us to carry out an effective and successful output.

Finally I would like to thank Sokoto State Scholarship Board of Nigeria for offering me scholarship that provided me an opportunity to advance my education and professional development beyond the field of Chemistry at Kulliyyah of Pharmacy, International Islamic University Malaysia.  
Adulrashid Umar.

## TABLE OF CONTENTS

Abstract .....	ii
Abstract in Arabic .....	iii
Approval Page .....	iv
Declaration Page .....	v
Copyright Page .....	vi
Dedication .....	vii
Acknowledgements .....	viii
List of Tables.....	xiv
List of Figures .....	xv
List of Abbreviations.....	xvii
<b>CHAPTER ONE: INTRODUCTION .....</b>	<b>1</b>
1.1. Background and justification .....	1
1.2. Prevalence of diabetes in Malaysia .....	2
1.3. <i>Tetracera scandens</i> (Linn.) ( <i>T. scandens</i> L.) .....	4
1.4. General objectives.....	5
1.5. Specific objectives .....	5
1.6. Research Hypothesis .....	5
<b>CHAPTER TWO: REVIEW OF THE LITERATURE .....</b>	<b>6</b>
2.1. Medicinal Plants: An overview.....	6
2.2. Traditional medicine .....	9
2.3. Drug discovery from medicinal plants.....	10
2.4. Future drugs from plants.....	13
2.5. Synthesis and role of plant secondary metabolites .....	15
2.6. Terpenes .....	16
2.6.1. Monoterpenes .....	17
2.6.2. Diterpenes.....	18
2.6.3. Triterpenes.....	19
2.6.4. Sesquiterpenes .....	20
2.7. Phenolic compounds .....	21
2.7.1. Flavonoids .....	22
2.7.2. Isoflavonoids .....	23
2.8. Nitrogen containing compounds .....	24
2.8.1. Alkaloids .....	25
2.9. Cyanogenic glycosides.....	27
2.10. Present drugs for treatment of diabetes mellitus .....	29
2.11. Antidiabetic plants .....	31
2.12. Dilleniaceae: An overview.....	37
2.12.1. Vegetative Morphology .....	37
2.12.2. <i>Tetracera alnifolia</i> Willd.....	38
2.12.3. <i>Tetracera volubilis</i> Linn.....	39
2.12.4. <i>Tetracera asperula</i> Miq.....	39
2.12.5. <i>Tetracera costata</i> D.....	39

2.12.6. <i>Tetracera tigarea</i> D. ....	40
2.12.7. <i>Tetracera macrophylla</i> Wall. ....	40
2.12.8. <i>Tetracera indica</i> Merr. ....	40
2.12.9. <i>Tetracera scandens</i> (Linn.) Merr.( <i>T. scandens</i> L.):An overview ..	41
<b>CHAPTER THREE: MATERIALS AND METHODS</b> .....	<b>45</b>
3.1. Materials.....	45
3.1.1. Chemicals .....	45
3.1.2. Instruments .....	45
3.2. Methods.....	46
3.2.1. Animal study .....	46
3.2.2. Antidiabetic activity of polar and non-polar extracts .....	47
3.2.3. Plant material.....	47
3.3. Acute toxicity study .....	50
3.4. Induction of diabetes .....	50
3.4.1. Experimental design.....	51
3.5. Statistical analysis .....	53
3.6. Phytochemical investigations and characterizations.....	53
3.6.1. Determination of total Phenolic content.....	53
3.6.2. Determination of total flavonoid content .....	53
3.6.3. Determination of different classes of organic compounds.....	54
3.7. Isolation & purification of phytoconstituents. ....	54
3.7.1. Chromatographic purification of the extracts.....	54
3.7.1.1. DCM extract.....	55
3.7.1.2. EtOAc extract.....	56
3.7.1.3. Purifications of the compounds of EtOAc extract.....	57
3.7.1.4. Combined fractions 96-115 .....	57
3.7.1.5. Combined fractions 116-126 .....	57
3.7.1.5. Combined fractions 116-126.....	58
3.7.1.6. BuOH extract.....	60
<b>CHAPTER FOUR: RESULTS</b> .....	<b>63</b>
4.1. Anti-diabetic activity of the leaves of <i>T. scandens</i> L. <i>in vivo</i> .....	63
4.1.1. Acute toxicity study: .....	63
4.1.2. Determination of antidiabetic activity of AQ & MEOH extracts....	65
4.1.3. Determination of antidiabetic activity of DCM, EtOAc & BuOH... 71	
4.1.4. Statistical analysis .....	74
4.2. Phytochemical investigations & characterization of the leaves of <i>T. s.</i> .....	75
4.2.1. Total phenolic & flavonoid contents of polar extracts. ....	75
4.2.2. Phytochemical analysis .....	75
4.2.3. Isolation & structure elucidation of purified compounds (I).....	76
4.2.3. Isolation and structure elucidation of purified compounds (II).....	76
4.2.4. Isolation and structure elucidation of purified compounds (III). ....	78
<b>CHAPTER FIVE: DISCUSSION</b> .....	<b>82</b>
5.1. Antihyperglycemic activity of the leaves of <i>T. scandens</i> L. <i>in vivo</i> .....	82
5.2. Phytochemical investigations and structure characterizations.....	84
5.2.1. Spectroscopy .....	84
5.2.2. Isolation of terpenoids and flavonoids .....	85

CHAPTER SIX: CONCLUSION .....	114
6.1. Suggestions for further and future reference work .....	116
<b>BIBLIOGRAPHY</b> .....	118
OUT COME OF THIS THESIS WORK .....	130
Confrence and symposium presentations .....	130
Appendix 1a <sup>1</sup> HNMR of NP1 (Stigmasterol).....	133
1b <sup>1</sup> HNMR of NP1 (Stigmasterol).....	134
1c <sup>13</sup> C Nmr of NP1 (Stigmasterol).....	135
1d <sup>13</sup> C Nmr (apt) of NP1 (Stigmasterol).....	136
1e IR of NP1 (Stigmasterol).....	137
1f Mass of NP1 (Stigmasterol).....	138
Appendix 2a <sup>1</sup> HNMR of NP2 (Betulinic acid).....	139
2b <sup>1</sup> HNMR of NP2 (Betulinic acid).....	140
2c <sup>13</sup> C Nmr (apt) of NP2 (Betulinic acid).....	141
2d <sup>13</sup> C Nmr (apt) of NP2 (Betulinic acid).....	142
2e <sup>13</sup> C Nmr (apt) of NP2 (Betulinic acid).....	143
2f <sup>13</sup> C Nmr (apt) of NP2 (Betulinic acid).....	144
2g IR of NP2 (Betulinic acid).....	145
2h MASS of NP2 (Betulinic acid).....	146
Appendix 3a <sup>1</sup> HNMR of NP3 (isomeric mixture of sitosterol ( $\Delta^5$ ) glycoside and stigmasterol ( $\Delta^{5.22}$ ) glycoside).....	146
3b <sup>1</sup> HNMR of NP3 (isomeric mixture of sitosterol ( $\Delta^5$ ) glycoside and stigmasterol ( $\Delta^{5.22}$ ) glycoside).....	147
3c <sup>13</sup> C NMR of NP3 (isomeric mixture of sitosterol ( $\Delta^5$ ) glycoside and stigmasterol ( $\Delta^{5.22}$ ) glycoside).....	148
3d <sup>13</sup> C NMR (apt) of NP3 (isomeric mixture of sitosterol ( $\Delta^5$ ) glycoside and stigmasterol ( $\Delta^{5.22}$ ) glycoside).....	149
3e <sup>13</sup> C NMR (apt) of NP3 (isomeric mixture of sitosterol ( $\Delta^5$ ) glycoside and stigmasterol ( $\Delta^{5.22}$ ) glycoside).....	150
3f <sup>13</sup> C NMR (apt) of NP3 (isomeric mixture of sitosterol ( $\Delta^5$ ) glycoside and stigmasterol ( $\Delta^{5.22}$ ) glycoside).....	151
3g <sup>13</sup> C NMR of NP3 (isomeric mixture of sitosterol ( $\Delta^5$ ) glycoside and stigmasterol ( $\Delta^{5.22}$ ) glycoside).....	152
3h IR of NP3 (isomeric mixture of sitosterol ( $\Delta^5$ ) glycoside and stigmasterol ( $\Delta^{5.22}$ ) glycoside).....	153
3i MASS of NP3 (isomeric mixture of sitosterol ( $\Delta^5$ ) glycoside and stigmasterol ( $\Delta^{5.22}$ ) glycoside).....	153
Appendix 4a <sup>1</sup> HNMR of PA (Kaempferol).....	153
4b <sup>1</sup> HNMR of PA (Kaempferol).....	154
4c <sup>13</sup> C NMR (apt) of PA (Kaempferol).....	155
4d IR of PA (Kaempferol).....	156
4e MASS of PA (Kaempferol).....	157
Appendix 5a <sup>1</sup> HNMR of PB (Quercetin).....	158
5b <sup>1</sup> HNMR of PB (Quercetin).....	158
5c <sup>1</sup> HNMR of PB (Quercetin).....	159
5d <sup>13</sup> C NMR (apt) of PB (Quercetin).....	160

5e IR of PB (Quercetin) .....	161
5f MASS of PB (Quercetin).....	162
Appendix 6a <sup>1</sup> HNMR of PHB (Isoscutellarein).....	163
6b <sup>13</sup> C NMR (apt) of PHB (Isoscutellarein).....	164
6c IR of PHB (Isoscutellarein).....	165
6d MASS of PHB (Isoscutellarein).....	166
Appendix 7a <sup>1</sup> HNMR of PC (5, 7, 8, 3', 5'-pentahydroxyflavone).....	167
7b apt <sup>13</sup> C NMR of PC (5, 7, 8, 3', 5'-pentahydroxyflavone) .....	168
7c H-H COSY of PC (5, 7, 8, 3', 5' pentahydroxyflavone).....	169
7d HSQC of PC (5, 7, 8, 3', 5'-pentahydroxyflavone) .....	170
7e Hmhc of PC (5, 7, 8, 3', 5'-pentahydroxyflavone) .....	171
7f IR of PC (5, 7, 8, 3', 5'-pentahydroxyflavone) .....	172
7g MASS of PC (5, 7, 8, 3', 5'-pentahydroxyflavone).....	173
Appendix 8a <sup>1</sup> HNMR of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	174
8b <sup>1</sup> HNMR of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	175
8c <sup>1</sup> HNMR of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	176
8d <sup>1</sup> HNMR of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	177
8e <sup>1</sup> HNMR of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	178
8f <sup>1</sup> HNMR of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	179
8g apt <sup>13</sup> C NMR of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	180
8h apt <sup>13</sup> C NMR of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	181
8i apt <sup>13</sup> C NMR of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	182
8j apt <sup>13</sup> C NMR of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	183
8k H-H COSY of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	184
8l HSQC of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	185
8m HMBC of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	186
8n HMBC of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	187
8o HMBC of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	188
8p HMBC of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	189
8q HMBC of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')- kaempferol-3''-O-β-D-glucopyranoside).....	190
8r IR of PE ((2, 3, 5, 6, 4'-pentahydroxy stilbene-(4→O→4''')-kaempferol- 3''-O-β-D-glucopyranoside) .....	191

Appendix 9c TLC of PA, PB, PC, PD and PE.....	191
9b TLC of PC, PHB and PD and PE from Ethyl acetate and butanol extract.	192
9c TLC of PA from ethyl acetate extract .....	193
9d TLC of PB from ethyl acetate extracts.....	194
9e TLC of PHB from ethyl acetate extract .....	195
9f TLC of PC from ethyl acetate extract.....	196
9g TLC of PD from ethyl acetate extracts.....	197

## LIST OF TABLES

<u>Table No.</u>		<u>Page No.</u>
3.1	Physical properties of isolated compounds	59
4.1	Acute toxicological evaluation of the AQ and MeOH extracts of the leaves of <i>T.S</i>	62
4.2	Effect of different doses of AQ extract of the leaves of <i>T. scandens</i> L.	64
4.3	Effect of different doses of MeOH extract of the leaves of <i>T. scandens</i> L.	67
4.4	Effect of DCM, EtOAc, and BuOH extracts of the leaves of <i>T. scandens</i> L.	70
5.1	Comparison of NP-1 (DMSO-d <sub>6</sub> δppm) <sup>1</sup> H and <sup>13</sup> C-NMR (600 MHz)	85
5.2	Comparison of NP-2 (DMSO-d <sub>6</sub> δppm) <sup>1</sup> H and <sup>13</sup> C-NMR (600 MHz)	89
5.3	Comparison of <sup>1</sup> H and <sup>13</sup> C -NMR (600 MHz) chemical shifts of compound PA	94
5.4	Comparison of <sup>1</sup> H and <sup>13</sup> C -NMR (600 MHz) chemical shifts of compound PB	98
5.5	Comparison of <sup>1</sup> H and <sup>13</sup> C -NMR (600 MHz) chemical shifts of compound PHB	102
5.6	<sup>1</sup> H and <sup>13</sup> C-NMR, COSY and HMBC (600 MHz) chemical shift of compound PC	106
5.7	<sup>1</sup> H and <sup>13</sup> C-NMR, COSY and HMBC (600 MHz) chemical shifts of compound PE (δ (ppm) DMSO- d <sub>6</sub> , coupling constants (J) in Hz)	111

## LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
2.1	Structure of metformin (antidiabetic agent) derived from <i>Galega officinal</i>	8
2.2	The structure of artemisinin and arteether, antimalarial drugs	11
2.3	Schematic representation of a typical medicinal plant drug discovery process and development	12
2.4	Structure of Taxol, a potent anticancer drug derived from <i>Taxus brevifolia</i>	13
2.5	Biosynthesis of secondary metabolites	16
2.6	Monoterpenes commonly found in essential oils	17
2.7	Diterpene compounds	18
2.8	Triterpene compounds	19
2.9	Sesquiterpene $\alpha$ - Santonin, a potent anthelmintic drug	20
2.10	2-Phenylbenzopyrans (C6-C3-C6 Backbone)	21
2.11	Structures of the six main classes of flavonoids	23
2.12	Structures of some important isoflavonoids (phytoestrogens)	24
2.13	Structure of pseudoalkaloid, Mescaline, an entheogen	25
2.14	Structure of triterpene alkaloid, Solasodine	25
2.15	Structures of bisbenzylisoquinoline alkaloid tetrandrine	26
2.16	Different types of cyanogenic glycosides	28
2.17	<i>Tetracera scandens</i> (Linn.) Merr	40
3.1	Flow chart for the extraction process of animal studies	47
3.2	Flow chart for the extraction process, isolation and purification of phytoconstituents	61



4.1	Effect of different doses of AQ extract of the leaves of <i>T. scandens</i> L. of diabetic rats (Mean $\pm$ S.D)	66
4.2	Effect of different doses of AQ extract of the leaves of <i>T. scandens</i> L. of normal rats (Mean $\pm$ S.D)	67
4.3	Percentage fall of blood glucose of different doses of AQ extract of of <i>T. Scandens</i> L. (mmol/L) on diabetic rats	67
4.5	Effect of different doses of MeOH extract of the leaves of <i>T. scandens</i> L. of normal rats (Mean $\pm$ S.D)	69
4.6	Percentage fall of blood glucose of different doses of MeOH extract of of <i>T. scandens</i> L. (mmol/L)	70
4.7	Effect of different doses of BuOH, EtOAc and DCM extract of the leaves of <i>T. scandens</i> L. in diabetic rats (Mean $\pm$ S.D)	72
4.8	Effect of different doses of BuOH, EtOAc and DCM extract of the leaves of <i>T. scandens</i> L. in normal rats (Mean $\pm$ S.D)	72
4.9	Effect of BuOH, EtOAc and DCM extract of the leaves of <i>T. scandens</i> L. on blood glucose levels (mmol/l) in diabetic rats at different intervals (hours)	73
5.1	NP1 as (24R)-24-ethyl-5a-cholesta 5, 22-dien-3 $\beta$ -ol (Stigmasterol)	88
5.2	NP-2 as 3 $\beta$ -3-Hydroxy-lup-20(29)-en-28-oic acid (Betulinic acid)	92
5.3	PA as Kaempferol (4', 3, 5, 7-tetrahydroxyflavone, C <sub>15</sub> H <sub>10</sub> O <sub>6</sub> )	96
5.4	PB as Quercetin; 3', 4', 3, 5, 7-pentahydroxyflavone. C <sub>15</sub> H <sub>10</sub> O <sub>7</sub>	100
5.5	PHB as 5, 7, 8, 4'-tetrahydroxyflavone (Isoscutellarein), C <sub>15</sub> H <sub>10</sub> O <sub>6</sub>	104
5.6	PC as 5, 7, 8, 3', 5'-pentahydroxyflavone, C <sub>15</sub> H <sub>10</sub> O <sub>7</sub>	108
5.7	PE as 2, 3, 5, 6, 4'-pentahydroxy stilbene-(4 $\rightarrow$ O $\rightarrow$ 4''')-kaempferol-3'''-O- $\beta$ -D-glucopyranoside	113

## LIST OF ABBREVIATIONS

Anova	Analysis of Variance
AlCl <sub>3</sub>	Aluminum chloride
BuOH	Butanol
DCM	Dichloromethane
DM	Diabetes Mellitus
MgCl <sub>2</sub>	Magnesium Chloride
MS	Mass spectrometry
ppm	parts per million
SAR	Structure Activity Relationship
TMS	Trimethylsilane
TLC	Thin Layer Chromatography
FA	Formic acid
nm	Nanometer
UV	Ultraviolet
R <sub>f</sub>	Retention factor
MeOH	Methanol
EtoH	Ethanol
EtoAc	Ethyl acetate
<sup>1</sup> H	Proton
<sup>13</sup> C	Carbon 13
NMR	Nuclear Magnetic Resonance
IR	Infrared
KBr	Potassium bromide
NaOMe	Sodium methoxide
NaOAc	Sodium acetate
Me	Methyl group
Hz	Hertz
MHz	Mega hertz
H <sub>3</sub> BO <sub>3</sub>	Boric acid
HCl	Hydrochloric acid
H <sub>2</sub> SO <sub>4</sub>	Sulphuric acid
NaOH	Sodium hydroxide
NaCl	Sodium chloride
Na <sub>2</sub> CO <sub>3</sub>	Sodium carbonate
Na <sub>2</sub> SO <sub>4</sub>	Sodium sulphate
ml	milliliter
mg/kg	milligram/kilogram
mg/ml	milligram/kilogram
1M	One molar
mmol	millimole
o	<i>ortho</i>
m	<i>meta</i>
p	<i>para</i>
V/H <sub>2</sub> SO <sub>4</sub>	Vannilin/ Sulphuric acid
FeCl <sub>3</sub>	Ferric Chloride

QE	Quercetin equivalent
GAE	Gallic acid equivalent
Su	Sulfonylurea
BG	Biguanide
$\alpha$ -GDI	A-Glucosidase inhibitors
ARI	Aldose reductase inhibitors
TDZ	Thiazolidinediones
CMBA	Carbamoylmethyl benzoic acid
IGF	Insulin-like growth factor
IDDM	Insulin dependent diabetes mellitus
NIDDM	Non insulin dependent diabetes mellitus
WHO	World Health Organization
LD <sub>50</sub>	Medium lethal dose
SPSS	Statistical package for social sciences
OGTT	Oral glucose tolerance test
GLBC	Glibenclamide
FCR	Folin-ciocalceu reagent

# **CHAPTER ONE**

## **INTRODUCTION**

### **1.1 BACKGROUND AND JUSTIFICATION**

Diabetes mellitus is a metabolic disease which is characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The vast majority of cases of diabetes fall into two broad etiopathogenetic categories. In one category, type-1 diabetes, in which the cause is an absolute deficiency of insulin secretion. While the other is much more prevalent category, which is type-2 diabetes, where by the cause is a combination of resistance to insulin action as well as inadequate compensatory insulin-secretory response (Li et al., 2004).

Type-1 insulin-dependent diabetes mellitus (IDDM), in which the body does not produce any insulin, most often occurs in children and young adults. It accounts for 5-10% of diabetes (Jeffery et al., 2003).

Type-2, non insulin-dependent diabetes mellitus (NIDDM), in which the body does not produce enough, or properly use, insulin, is the most common form of the disease, accounting for 90-95% of the dreading disease of diabetes. Type-2 diabetes is nearing epidemic proportions, due to an increased number of elderly people, and a greater prevalence of obesity and sedentary lifestyles. As a very common chronic disease, diabetes is becoming the third “killer” of the health of mankind along with cancer, cardiovascular and cerebrovascular diseases because of its high prevalence, morbidity and mortality (Li et al., 2004).

The cause of diabetes is a mystery, although both genetic and environmental factors such as obesity and lack of exercise appear to play a role. Ethnic and racial

differences have been found in heterogeneous populations within the same area. As a rule, incidence is highest in Scandinavian countries, intermediate in the US, Spain and lowest in Asian and most Latin American countries. With long course and serious complications often resulting in high death-rate, the treatment of diabetes spent vast amounts of resources including medicines, diets, physical training and so on in all countries (Li et al., 2004).

According to the WHO estimate, the number of diabetics will increase to 300 million by year 2025 (Jeffery et al., 2003). Total health care spending on the disease worldwide is estimated to be US\$ 213 billion and US\$ 396 billion by the year 2025. It was predicted that 75% to be from developing countries because of rapid cultural and social changes and also increasing urbanisation, with this scenario, diabetes will burden the health care system, which is already strained with other chronic diseases such as coronary heart disease, asthma, hypertension, kidney failure etc. Adequate blood glucose control is vital in diabetes management to prevent complications. Yet, despite the various interventions, diabetes control remains a global problem to health care professionals (HCPs). More people suffer from diabetes due to the increase in the level of obesity and other related factors worldwide (Jeffery et al., 2003).

## **1.2 PREVALEANCE OF DIABETES IN MALAYSIA**

There is a growing number of people diagnosed with diabetes, but with the growing number of people diagnosed with diabetes, Malaysia is not spared of this phenomenon, as prevalence stands at 14.9% of adult population. Adequate blood glucose control is vital in diabetes management to prevent complications, rapid changes, with the prospect of a changing health scenario, has led Malaysians to be affected by western health problems (Jeffery et al., 2003 & Ismail et al., 2001). As of

2001, study noted that 10% of the Malaysian population were diagnosed diabetics (Ismail et al., 2001). Studies also found that the majority of diabetics did not have their disease under control, where 61.1% of patients had HbA1c greater than 8.0%. The studies found that 87.1% of them were hypertensive, 63.5% had a family history of diabetes, 51.6% were not on any hypertensive medications, and 37.2% had microalbuminuria (Ismail et al., 2001).

Complications of diabetes have caused Malaysia to be ranked as number one in kidney failure. A great concern as it implied that diabetes was not well controlled in Malaysia. The number of Malaysians suffering from end-stage renal failure has increased more than 56-fold between 1980 and 2007 (from 43 in 1980 to 12,000) there could also be more unregistered cases. To tackle this problem, the Ministry of Health (MOH) has embarked on a new strategy to reduce these alarming figures through educating, counselling and getting doctors' cooperation. Among these measures are applying new knowledge and innovations gained from multiple sources and disciplines to ensure much needed changes in the health care system for example, the use of genetic informatics and role of genetic markers in risk of chronic diseases of diabetes and cardiovascular diseases, implementing new strategies and understanding behaviour of patients to achieve better health (Merican, 2008).

Despite various measures taken, there is still lack of diabetic control among people with diabetes in Malaysia and there is a need to understand clearly regarding this situation and hopefully the Natural product diabetic research could provide a significant contribution for alliviating such dreading disease from our societies.

The field of herbal medicines research has been gaining significant importance in the last few decades and the demand to use natural products in the treatment of diabetes is increasing worldwide. The available literature shows that there are more

than 400 plant species showing antidiabetic activity (Rai, 1995). Therefore it is prudent to look for alternatives in exploring herbal medicines for diabetes as well. Although, herbal medicines have long been used effectively in treating diseases in many countries of the world, the mechanism of most of the herbals used has not been clearly defined. Many traditional plant treatments were used for treating diabetes, but most of the evidence for their scientific effects is anecdotal (Prasad et al., 2009). Hence traditional antidiabetic plants might provide new oral hypoglycemic compounds, which can counter the high cost and poor availability of the current medicines/ present day drugs for many rural populations in developing countries.

### **1.3 *TETRACERA SCANDENS* (LINN.) (*T. SCANDENS* L.):**

(Family: Dilleniaceae) (local Malaysian name- mempelas kasar) is a climbing vine growing from 3 to 5 meters or more in length and grows widely in India, southern China, Indonesia, Myanmar, Philippines, Thailand, Vietnam and Malaysia.

Different parts (leaves, stems and roots) of *T. scandens* L. are used in folk remedies by various indigenous people in different countries for the treatment of rheumatism, lowering blood pressure, inflammatory diseases, hepatitis, internal pains, urinary disorders, dysentery, child birth, sore throat, gout and diabetes related infirmities (Tawan, 2001; Werner, 2002; Nguyen et al., 2004; Purkayastha et al., 2007; Myung et al., 2009).

The polar extracts of *T. scandens* L. have been reported to exhibit potential therapeutic Xanthenes Oxidize (XO) inhibitory activity in a concentration-dependent manner *in vitro* (Nguyen et al., 2004). Isoflavonoids isolated from the leaves of *T. scandens* L., have been shown to exert significant glucose uptake effect in basal and insulin-stimulated L6 Myotubes *in vitro* suggesting its potential in the management of

diabetes (Myung et al., 2009). However, no scientific report of this plant *in vivo* has ever been recorded or mentioned in literature showing an antidiabetic efficacy of the leaves of *T. scandens* L. with respect to confirm its utility in folkloric medicine by the local herbalists in Malaysia.

#### **1.4 GENERAL OBJECTIVES**

- To scientifically prove the traditional claims of the leaves of *T. scandens* L. in the treatment of diabetes related infirmities in Malaysia using animal models (*in vivo*).
- To investigate phytoconstituents of the leaves of *T. scandens* L.

#### **1.5 SPECIFIC OBJECTIVES**

- To prepare polar and non-polar extracts of the leaves of *T. scandens* L.
- To investigate antidiabetic activity of polar and non-polar extracts *in vivo*.
- To isolate and characterize the structures of phytoconstituents present in polar and non-polar extracts of the leaves of *T. scandens* L.
- Establish a scientific basis for the therapeutic use of *T. scandens* L.

#### **1.6 RESEARCH HYPOTHESIS**

- *T. scandens* L. might contain therapeutically active principles which could play a lead role towards the management of diabetes.
- Active principles could be isolated and their structures could be characterized through chemical and spectral analysis.